UK’s NHS Facing Major Leadership Shake-Up
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Address: Janssen, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, United Kingdom
Tel: +44 (0) 1494 567567
Web: http://www.janssen.co.uk/
In 1947, Ortho Pharmaceuticals was brought into the Johnson & Johnson group of companies and set up a UK base in Lane End, Buckinghamshire.
Johnson & Johnson’s pharmaceutical interests expanded over the next decades with the addition of the Swiss company Cilag Chemie in 1959 and the Belgian company Janssen Pharmaceutica in 1961. Both of these companies had grown from small research laboratories into successful multinationals.
Ortho moved to a site in Saunderton, Buckinghamshire in the early 1950s. Janssen established its first British offices in Marlow, Buckinghamshire, in 1974 and moved to Grove in Oxfordshire a decade later.
Ortho became Ortho Cilag in 1982 and then Cilag in 1988. On 1st January 1995, Cilag and Janssen merged to become Janssen-Cilag Ltd and all operations were transferred to the Saunderton site. In May 2008, the company moved to new offices in High Wycombe.
In September 2000, Ortho Biotech was established, a company specialising in treatments for conditions such as renal disease and cancer.
Tibotec was established in 1994 as a drug discovery laboratory, it evolved to a fully integrated pharmaceutical company focussing on the discovery and the development of new drugs for infectious diseases. In April 2002, Tibotec was acquired by Johnson & Johnson and became a division of Janssen-Cilag.
In 2010, Janssen-Cilag became Janssen and now employs more than 400 people. Its head office is in High Wycombe, Buckinghamshire and also has an office in Dublin.
Janssen is one of the world’s leading research-based pharmaceutical companies, with operations throughout the world. In the UK, Janssen employs more than 400 people.
The company is committed to delivering great medicines and has introduced a range of innovative treatments that can make an important difference to the lives of patients with serious health conditions such as schizophrenia, epilepsy, multiple myeloma and HIV/AIDS. Janssen has one of the strongest development pipelines in the industry with research now focusing on five key areas. These key areas are: neuroscience, oncology, immunology, metabolism and infectious diseases.
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association…
After a tumultuous year, AstraZeneca is creating a standalone vaccine unit and will begin to charge for its COVID-19 vaccine shot, having previously provided it at cost. PharmaBoardroom looks back…
The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over…
Cyril Titeux, senior VP mid-sized markets EMEA & strategic leader at Janssen, argues that the current focus of many health systems on efficiency, streamlining, and reducing spending is leaving them…
British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again finding itself under the spotlight as analysts and shareholders alike continue to query the…
Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the International Society of Paediatric Oncology (SIOP) discusses the latest advancements in childhood cancer treatment, the…
Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient and patient organizations’ involvement in the decision-making process for therapy appraisals, the use of HTA,…
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of…
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest acquisition; and calls for a national registry to…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on NASDAQ, raising over USD 30 million. Founded…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left…
See our Cookie Privacy Policy Here
